Drug intelligence / Profile preview

DE-111

Development stage: Phase 3
Modality: Small Molecules
Administration: Ophthalmic

Overview

DE-111 is an investigational ophthalmic solution developed for the treatment of open-angle glaucoma and ocular hypertension. Its primary purpose is to lower intraocular pressure (IOP) in affected patients. The specific mechanism of action, molecular target, and active ingredient for DE-111 have not been disclosed in publicly available sources as of May 2025. Clinical evaluation has focused on safety and efficacy in reducing IOP in a multicenter, open-label study involving patients with these conditions[6].

Other names: DE-111DE111DE 111

Beyond the preview

Go deeper on DE-111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DE-111.

Explore the full profile